Építés alatt – nem éles oldal
Belépés
Résztvevőt keres1/2. fázis

A Clinical Trial of EHT102 Injection in Pediatric Patients With Biallelic hOTOF Mutations

A legfontosabb adatok

Ki végzi
Shanghai Euhearing Therapeutics Co., Ltd
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
1/2. fázis
Résztvevők
30 fő, tervezett
Kezdés
2026. ápr. 2.
Várható befejezés
2033. dec. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • EHT102 Injection
A regiszteradat frissítve
2026. április 14.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for children aged 1 to 17 born with severe hearing loss caused by changes in both copies of the OTOF gene (DFNB9). They receive a single EHT102 injection into the ear.

Életkor
1 to 17 years
Nem
All sexes
A betegség stádiuma
Congenital (present from birth) severe or profound hearing loss of 65 dB or more on an ABR hearing test. The first participant must have an ABR above 90 dB. The child must be fit enough for ear surgery, with no ear or hearing nerve malformations and no active ear inflammation on CT or MRI.
Korábbi kezelés
Cannot join after ototoxic drugs (e.g., aminoglycosides, cisplatin, loop diuretics) in the past 6 months, antiviral or immune therapy in the past 3 months, or live vaccines in the past 30 days. Cannot join after a gene therapy trial in the past 6 months.
Biomarker vagy leletérték
Genetic test showing DFNB9 deafness with biallelic mutations (changes in both copies) of the Otoferlin (OTOF) gene. DPOAE hearing test must show a response.

A részvétel fő kizáró okai

  • Other types of hearing loss, such as conductive, mixed or syndromic deafness with malformations
  • Ear conditions such as otitis media, Ménière's disease, acoustic neuroma
  • Cochlear implant or other implanted device in the ear to be treated
  • Weak immune system, organ transplant, HIV, hepatitis B or C, or active syphilis
  • Serious other diseases, nerve or mental health disorders, or being unable to have surgery or anesthesia

A regiszter feltételei, szó szerint

Mind a 26 feltétel megnézéseKevesebb

Ki vehet részt

  • Prior to study participation, participants and/or their legal guardians must provide informed consent for this trial, voluntarily sign the written informed consent form (ICF), and commit to completing all protocol-specified follow-up visits
  • Participants must be able to communicate effectively with investigators and comply with study requirements, with guardian assistance if needed. For young children without developed language skills, guardians must ensure cooperation with investigator instructions
  • Participants and/or their legal guardians must demonstrate adequate comprehension of the trial's nature and maintain realistic expectations regarding potential benefits
  • Pediatric patients (male or female) aged ≥ 1 and ≤ 17 years at the time of inclusion
  • Genetic testing report indicates DFNB9 congenital deafness with Biallelic mutations in the Otoferlin gene
  • Severe or profound hearing loss (≥65 dB) assessed by ABR, with the sentinel participant having an ABR >90 dB
  • Meet eligibility criteria for otologic surgery: Absence of middle/inner ear malformations, cochleovestibular nerve abnormalities, or active otologic inflammation as confirmed by computed tomography (CT) and/or magnetic resonance imaging (MRI) within 3 months or during screening period, with surgical suitability determined by the investigator
  • DPOAE testing shows present response

Ki nem vehet részt

  • Have other types of hearing loss ineligible for otologic surgery, including but not limited to:; Middle/inner ear malformations or developmental abnormalities identified by CT/MRI within 3 months; Hearing loss caused by cochleovestibular nerve abnormalities; Conductive hearing loss ; Mixed hearing loss; Syndromic deafness with malformations
  • Have a history of receiving any known ototoxic medications (e.g., aminoglycosides, cisplatin, loop diuretics) within the past 6 months
  • Antiviral/immunotherapy within 3 months prior to screening
  • Administration of any live-attenuated vaccines within 30 days prior to screening
  • Have contraindications to surgery or anesthesia as determined by the surgeon, anesthesiologist, or designated personnel, including but not limited to:; History of cardiovascular or cerebrovascular events within the past 6 months (e.g., myocardial infarction, heart failure, angina, stroke, or transient ischemic attack) Any other cardiac conditions deemed unsuitable for study participation by the investigator; Known hypersensitivity to the investigational drug
  • Have participated in gene therapy trials within 6 months prior to screening, plan to participate in other interventional clinical trials within one year post-treatment, or have received investigational drugs within 5 half-lives of the last dose from previous trials
  • Have implantable devices (e.g., cochlear implants) in the target ear at screening
  • Have chronic anticoagulant therapy that cannot be temporarily discontinued
  • Females of childbearing potential with positive pregnancy tests prior to dosing; Females of childbearing potential and non-sterilized males with fertile partners unwilling/unable to use effective contraception from ICF signing until ≥24 months post-dosing
  • Have pre-existing otologic conditions deemed by the investigator to potentially compromise the planned surgery or interfere with study endpoint evaluation, including but not limited to:; Acute/chronic otitis media;; Ménière's disease; Acoustic neuroma; Unresolved sudden sensorineural hearing loss
  • Have a history of drug abuse
  • Have immunocompromised status or immunodeficiency disorders, including but not limited to:; Positive HIV antibody (HIV Ab) test; Congenital or acquired immunodeficiency (investigator-determined contraindication to immunosuppressants) ; History of organ transplantation
  • Have severe systemic diseases or acute conditions, including but not limited to:; Active tuberculosis; Active herpes zoster infection; Pancreatitis; Renal insufficiency; Gastrointestinal ulcers
  • Have other severe congenital disorders
  • Have a history of neurological/psychiatric disorders (e.g., epilepsy, dementia)
  • Have a history of radiotherapy/chemotherapy deemed by investigators to potentially affect trial outcomes
  • Have tested positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis C virus (HCV) antibody with HCV RNA positive, or positive for human immunodeficiency virus (HIV) antibody, or have active syphilis (TPPA positive and RPR positive)
  • Any other condition that, at the discretion of the investigator, renders the participant unsuitable for enrollment

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 1 és 17 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is a multicenter, single-arm, open-label Phase I/II clinical trial, which is designed to evaluate the safety, tolerability and efficacy of EHT102 injection in treating congenital hearing loss secondary to biallelic mutations of OTOF (DFNB9).Up to 30 pediatric participants (A maximum of 15 participants will be enrolled in each of the United States and China) will be enrolled and dosed with EHT102. The dose-escalation phase (Phase I) includes two predefined dose cohorts (3 participants per cohort), with sequential enrollment from low to high dose. During dose escalation, each participant will receive a unilateral EHT102 injection followed by safety observation.

A vizsgálat 2 csoportja

  • The low-dose cohortA vizsgált kezelés

    Participants will receive a single unilateral or bilateral administration of EHT102 at the defined low dose level

    Kezelés: EHT102 Injection

  • The high-dose cohortA vizsgált kezelés

    Participants will receive a single unilateral or bilateral administration of EHT102 at the defined high dose level.

    Kezelés: EHT102 Injection

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase Ⅰ/Ⅱ, Multicenter, Single-arm, Open-label Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHT102 Injection in Pediatric Patients With Biallelic hOTOF Mutations
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT07288580: ki vehet részt
A regiszteradat frissítve
2026. április 14.